IngredientesPotassium is a chemical element with the symbol K, derived from the Neo-Latin word kalium, and bears atomic number 19. The symbol K is derived from kali (alkali), which in turn comes from the Arabic word for plant ashes, al-qalyah. It is a silvery-white metal that is soft enough to easily cut with a knife. In biological and nutritional contexts, potassium is not encountered as a free metal but exclusively as a monovalent cation (K⁺). In the periodic table, potassium is one of the alkali metals, all of which have a single valence electron in the outer electron shell easily removed to create a positively charged ion; in nature, potassium occurs only in ionic salts.
Potassium (CASRN 7440-09-7) is a requirement for most living things and is found in an abundance of approximately 2.5% in the Earth's crust. Discovered in 1807 by Sir Humphry Davy, this metal is among the most highly reactive, being particularly explosive when coming into contact with water. In ratio of abundance, potassium is the 20th most abundant element in the solar system and the 17th most abundant on Earth, comprising around 2.6% of the weight of the Earth's crust.
In dietary supplements, potassium is often present as potassium chloride, but many other forms — including potassium citrate, phosphate, aspartate, bicarbonate, and gluconate — are also used. The Supplement Facts panel on a dietary supplement label declares the amount of elemental potassium in the product, not the weight of the entire potassium-containing compound.
Not all multivitamin/mineral supplements contain potassium, but those that do typically provide about 80 mg potassium. Potassium-only supplements are also available, and most contain up to 99 mg potassium. A 2016 dose-response trial found that humans absorb about 94% of potassium gluconate in supplements, and this absorption rate is similar to that of potassium from potatoes.
Although many foods contain potassium, vegetables and fruit are the richest sources. Vegetables, in particular beans, lentils, tomatoes, potatoes (particularly with the skin), sweet potatoes, soy, and winter squash are all good sources. Fruits that contain significant amounts include citrus fruits, cantaloupe, bananas, kiwi, prunes, and apricots. Milk, yogurt, and nuts are also good sources of potassium.
Potassium was discovered from the ashes of plants, and its name was derived from "potash" (plant ashes). In early practice, potassium was extracted by placing ashes of burnt trees in a pot along with water; the mixture was heated and the solution evaporated to obtain potash. Potassium was first isolated in pure elemental form in 1807 by Sir Humphry Davy, an English chemist and physicist, who conducted experiments using a voltaic pile (an early battery) to electrolyze potash — a mixture of potassium and sodium carbonates.
Since ancient times, potassium compounds were widely utilized for various purposes. Early civilizations, such as the Egyptians, Romans, and Greeks, recognized its preservative properties and used potassium nitrate, also known as saltpeter, in the preservation of food and preparation of mummies. In medieval Europe, "potash" (potassium carbonate obtained from ashes) was employed in glassmaking, dyemaking, and soap production.
In ancient medicine, potassium nitrate was used for a variety of purposes. It was believed to have diuretic properties, thought to be beneficial for treating conditions such as edema and kidney problems. Potassium nitrate was also used as a mild antiseptic, applied topically to wounds to prevent infection. In some traditional medical systems, potassium nitrate was used as a treatment for fevers; it was thought that its cooling effect when dissolved in water could help reduce body temperature.
Potassium's discovery was a turning point in chemistry, demonstrating the power of electrolysis to isolate pure elements. Its role in biological systems was later recognized, leading to its classification as an essential nutrient. The concept of potassium as a nutritional requirement evolved from early 19th-century chemistry through to the 20th century, when human physiological studies established its critical roles in electrolyte balance, nerve signaling, and cardiovascular function. The development of the Dietary Approaches to Stop Hypertension (DASH) dietary pattern in the 1990s helped bring potassium's role in blood pressure regulation to mainstream clinical awareness.
Potassium functions entirely in its ionic form, K⁺. Unlike botanically derived supplements, potassium has no secondary phytochemicals. All biological effects are attributable to the potassium cation itself, its electrochemical behavior, and its interactions with sodium, hormones, and transport proteins. The specific counterion (chloride, citrate, bicarbonate, gluconate, etc.) in a given supplement preparation may influence secondary properties — such as effects on acid-base balance — but the fundamental electrochemical activity is that of K⁺.
The potassium pump — specifically, the Na⁺–K⁺ ATPase — is defined as the primary transport system that maintains ionic imbalance by extruding three Na⁺ ions out of the cell and transporting two K⁺ ions into the cell, generating a net outward current that helps establish and maintain electrochemical gradients essential for action potentials. For every ATP molecule the pump uses, three sodium ions are exported and two potassium ions are imported, creating a net export of a single positive charge per pump cycle. The net effect is an extracellular sodium concentration approximately five times the intracellular concentration and an intracellular potassium concentration approximately 30 times the extracellular concentration.
The sodium-potassium pump was discovered in 1957 by the Danish scientist Jens Christian Skou, who was awarded the Nobel Prize for this work in 1997. All cells expend a large fraction of the ATP they produce — typically 30% and up to 70% in nerve cells — to maintain their required cytosolic Na⁺ and K⁺ concentrations. For neurons, the Na⁺/K⁺-ATPase can be responsible for up to three-fourths of the cell's energy expenditure.
The Na⁺/K⁺-ATPase maintains the sodium and potassium concentration differences between intracellular and extracellular spaces, pumping each against their concentration gradients. This ensures maintenance of the negative membrane potential, making the pump essential for the proper functioning of nerve cells and their ability to generate and transmit action potentials. If the resting membrane potential of nerve cells is not stabilized, nerve cells may fire when not needed or may not fire at all. If the Na⁺/K⁺-ATPase stops working, the concentration gradients of Na⁺ and K⁺ on the inside and outside of the cell may not be correct, which can interrupt cell signals, cause muscles not to contract, and lead to many other serious conditions.
Maintaining normal potassium concentrations in the extra- and intracellular fluid is critical for cell function. Potassium homeostasis is achieved by ensuring proper distribution between fluid compartments and by matching excretion with intake. The Na⁺-K⁺-ATPase pump facilitates K⁺ uptake into skeletal muscle, where most potassium is stored. Na⁺-K⁺-ATPase activity is stimulated by insulin and aldosterone. The kidneys regulate long-term potassium homeostasis by controlling the amount excreted through urine. Renal handling of K⁺ is mediated by several regulatory mechanisms, including an aldosterone-mediated feedback control, in which high extracellular K⁺ concentration stimulates aldosterone secretion (which enhances urinary K⁺ excretion), and a gastrointestinal feedforward control mechanism, in which dietary K⁺ intake increases K⁺ excretion.
Potassium and sodium both interact within the body: potassium is pulled into cells while sodium is pushed out, and this interaction helps power the transport of nutrients across cell membranes. Through natriuresis (promoting renal sodium excretion), reducing vascular smooth muscle reactivity, and modulating the renin-angiotensin-aldosterone system, adequate potassium intake counteracts the blood pressure-raising effects of sodium. Serum potassium is tightly controlled through homeostatic mechanisms. The primary determinants of renal excretion of potassium include sodium delivery to the distal nephron and urine flow, the renin–angiotensin–aldosterone system, vasopressin levels, and acid–base status.
Adequate intake of dietary potassium may benefit bone health. One proposed mechanism is via its effects on acid-base balance. Potassium-containing foods — such as fruits and vegetables — provide precursors to bicarbonate ions, which assist in buffering acids in the body to maintain neutral blood pH. If the diet is deficient in potassium, the body may pull calcium from bone; as potassium intake increases, more calcium content is preserved.
The 2005 DRI Report conceptualized potassium adequacy as follows: "In generally healthy people, frank hypokalemia is not a necessary or usual expression of a subtle dietary potassium deficiency… a typical dietary intake of potassium that gives rise to a serum potassium concentration somewhat greater than 3.5 mmol/L would still be considered inadequate if a higher intake of potassium prevents, reduces, or delays expression of certain chronic diseases or conditions, such as elevated blood pressure, salt sensitivity, kidney stones, bone loss, or stroke."
The Adequate Intake (AI) for potassium, according to the U.S. Panel on Dietary Reference Intake, is 4.7 g (120 mmol)/day for adults, based on the assessment of health benefits of potassium at this level on blood pressure, bone density, and risk of kidney stones. The World Health Organization (WHO) recommends a dietary potassium intake of 3.9 g (100 mmol) per day, or at least 90 mmol/day (3,510 mg/day), to reduce blood pressure and the risk of cardiovascular damage, stroke, and coronary heart disease.
In healthy people with normal kidney function, high dietary potassium intakes do not pose a health risk because the kidneys eliminate excess amounts in the urine. Although case reports indicate that very large doses of potassium supplements can cause heart abnormalities and death, the NASEM committee concluded that these reports do not provide sufficient evidence to set a Tolerable Upper Intake Level (UL). In addition, there is no evidence that high intakes of potassium cause hyperkalemia in adults with normal kidney function. Therefore, the committee did not set a UL for potassium.
Regarding supplement doses used in clinical research: a meta-analysis investigating optimal dosing found that potassium reduced systolic blood pressure by −2.10 mm Hg in normotensive populations. Potassium at dosages of ≤60 mmol/day and durations greater than 1 month reduced systolic blood pressure by −2.34 and −2.80 mm Hg, respectively. In kidney stone research, potassium citrate is the most studied form at doses typically used in clinical and prescription settings well above the 99 mg found in most over-the-counter supplements.
Evidence Level: Strong — multiple meta-analyses of RCTs
The relationship between dietary potassium intake and blood pressure has been known for a long time. Many cross-sectional and longitudinal prospective studies have detected an inverse relationship between dietary potassium intake and blood pressure.
A meta-analysis by Aburto et al. (2013) included 22 RCTs and 11 cohort studies addressing the effects of potassium supplementation on blood pressure, renal function, blood lipids, and catecholamine concentrations. They reported that an increase in potassium intake could reduce systolic blood pressure (SBP) by 3.49 mmHg (95% CI: 1.82 to 5.15) and diastolic blood pressure (DBP) by 1.96 mmHg (0.86 to 3.06) in adults with raised blood pressure.
A systematic review and meta-analysis specifically in hypertensive subjects performed a meta-analysis and meta-regression of RCTs with selective and validated long-term (≥4 weeks) potassium supplementation. Overall, potassium supplementation decreased SBP by 4.48 mmHg (95% CI 3.07–5.90) and diastolic blood pressure by 2.96 mmHg (1.10–4.82).
There was little evidence of a dose-response relationship between blood pressure decrease and potassium supplementation. However, lower baseline potassium intake (<90 mmol/day) was associated with a higher blood pressure-lowering effect, as were higher sodium intake (particularly ≥4 g/day) and a higher sodium-to-potassium ratio.
The FDA has approved the following health claim: "Diets containing foods that are a good source of potassium and that are low in sodium may reduce the risk of high blood pressure and stroke." Overall, the evidence suggests that consuming more potassium might have a favorable effect on blood pressure and stroke, and it might also help prevent other forms of cardiovascular disease. However, more research on both dietary and supplemental potassium is needed before firm conclusions can be drawn.
Evidence Level: Moderate to Strong — prospective cohort studies and one landmark RCT (SSaSS)
Potassium has received attention in stroke research because of substantial evidence from randomized controlled trials of a blood pressure-lowering effect of potassium supplementation in hypertensive subjects. Some, but not all, observational cohort studies have found an inverse association between potassium intake and stroke risk.
In a spline regression meta-analysis, a decrease in the pooled relative risk (RR) was observed up to around 90 mmol/day potassium intake (approximately 3,500 mg/day). At this level of intake, the RR for stroke was 0.78 (95% CI 0.70–0.86), while above it the RR flattened.
The landmark evidence in this area comes from the Salt Substitute and Stroke Study (SSaSS). SSaSS was an unblinded, cluster-randomised trial assessing the effects of potassium-enriched salt compared with regular salt among 20,995 Chinese adults with established stroke and older age and uncontrolled hypertension. The SSaSS demonstrated significant reductions in the risk of stroke (14%, p = 0.006), major cardiovascular events (13%, p < 0.001), and premature death (12%, p < 0.001) with potassium-enriched salt compared to regular salt over five years. The SSaSS showed these beneficial effects with no evidence of increased risk of clinical hyperkalemia.
The rationale for the salt substitute is that both high dietary sodium consumption and lower dietary potassium consumption are associated with elevated blood pressure levels. Potassium-enriched salt substitutes have a dual blood pressure-lowering effect because they remove sodium from the diet and add extra potassium.
The SSaSS intervention used a salt substitute composed of 70% sodium chloride and 30% potassium chloride, which differs from regular salt (100% NaCl). Investigators have noted that the relative contributions of sodium reduction and potassium augmentation to the observed blood pressure reduction remain a subject of ongoing analysis. The contribution of sodium reduction versus potassium increase to these effects is unknown. Additionally, the SSaSS population was at high baseline risk, and generalizability to populations with lower cardiovascular risk is not fully established.
Evidence Level: Moderate — observational studies are consistent; RCT evidence is limited
Kidney stones are most common in people aged 40 to 60. Stones containing calcium — in the form of calcium oxalate or calcium phosphate — are the most common type. Low potassium intakes impair calcium reabsorption within the kidney, increasing urinary calcium excretion and potentially causing hypercalciuria and kidney stones. Low urinary levels of citrate also contribute to kidney stone development.
Observational studies suggest an association between higher potassium intakes and lower risk of kidney stones. However, evidence was found insufficient to determine whether potassium supplements are effective because only one trial addressing this question met inclusion criteria for systematic review. Additional research is needed to fully understand the potential link between dietary and supplemental potassium and the risk of kidney stones.
Potassium citrate specifically has been studied in clinical settings for stone prevention, primarily because the citrate anion raises urinary pH and citrate concentration, inhibiting calcium crystallization. Cochrane and other systematic reviews (Phillips et al., 2015) have examined citrate salts for preventing and treating calcium-containing kidney stones, though the evidence base for potassium supplementation as an isolated intervention remains limited.
Evidence Level: Preliminary — observational data are consistent; clinical trial evidence is limited
Observational studies suggest that increased consumption of potassium from fruits and vegetables is associated with increased bone mineral density. This evidence, combined with evidence from metabolic studies and a few clinical trials, suggests that dietary potassium may improve bone health. The underlying mechanisms are unclear, but one hypothesis is that potassium helps protect bone through its effect on acid-base balance.
People who have high intakes of potassium from fruits and vegetables seem to have stronger bones. Eating more of these foods might improve bone health by increasing bone mineral density — a measure of bone strength. However, disentangling the effects of potassium specifically from the overall benefits of fruit and vegetable consumption remains methodologically challenging in observational studies.
Evidence Level: Preliminary — observational associations exist; clinical trial evidence is very limited and inconclusive
Potassium — both serum levels and, to a lesser extent, dietary intake levels — has been associated with incident diabetes. Lower levels of potassium have been found to be associated with a higher risk of diabetes in some studies.
In an observational study analyzing data from 84,360 women aged 34–59 years participating in the Nurses' Health Study, those in the highest quintile of potassium intake had a 38% lower risk of developing type 2 diabetes over 6 years of follow-up compared to those in the lowest quintile.
Evidence from the committee's supplemental literature search identified one randomized controlled trial on the effect of potassium supplementation on glucose control and tolerance. A 12-week pilot study randomized 27 African American adults with prediabetes to receive either potassium chloride or placebo. There was insufficient evidence to determine if potassium intake has a differential effect on individuals with diabetes with respect to cardiovascular and renal indicators.
Higher potassium intake has been associated with the slower decline of kidney function and lower incidence of cardiovascular complications in type 2 diabetic patients with normal renal function. However, higher potassium intake has also been associated with increased risk of hyperkalemia in people with diabetes. The applicability of the potassium AIs for persons with type 2 diabetes is uncertain and will likely need to be individualized in consultation with a health care provider, with consideration of the individual's kidney function, medication use, and serum potassium concentrations.
Reviewing six cohort studies analyzing the association between urinary potassium excretion (a marker for intake) and renal outcomes: in healthy subjects, a higher potassium intake and rate of potassium excretion were associated with a lower risk of chronic kidney disease. In people with mild kidney disease, higher potassium intake and excretion were associated with a lower risk of renal decline. In people with diabetes, a higher potassium excretion was associated with lower odds of renal replacement therapy or cardiovascular events.
Insufficient potassium intakes can increase blood pressure, kidney stone risk, bone turnover, urinary calcium excretion, and salt sensitivity (meaning that changes in sodium intakes affect blood pressure to a greater than normal extent). Severe potassium deficiency can cause hypokalemia — a serum potassium level of less than about 3.6 mmol/L.
Hypokalemia affects up to 21% of hospitalized patients, usually because of the use of diuretics and other medications, but it is rare among healthy people with normal kidney function.
Symptoms of hypokalemia include constipation, tiredness, muscle weakness, and not feeling well. More severe hypokalemia can cause increased urination, decreased brain function, high blood sugar levels, muscle paralysis, difficulty breathing, and irregular heartbeat. Severe hypokalemia can be life-threatening.
Prolonged diarrhea or vomiting, laxative abuse, diuretic use, eating clay, heavy sweating, dialysis, or using certain medications can cause severe potassium deficiency.
The following dosage information is drawn from the cited sources and refers to forms and amounts used in clinical or regulatory contexts:
Hyperkalemia (serum potassium concentration >5.0 mmol/L, which is the upper limit of normal) can lead to cardiac arrhythmias and, in extreme cases, cardiac death. Available evidence indicates that, in generally healthy individuals, excess potassium is excreted in the urine. Because they may have impaired potassium excretion, individuals with certain conditions — including chronic kidney disease, end-stage renal disease, diabetes, severe heart failure, or adrenal insufficiency — and those using certain medications such as ACE inhibitors and ARBs were identified as potentially vulnerable subpopulations in which potassium intakes at the AI may not be appropriate.
In individuals taking medications such as angiotensin converting enzyme (ACE) inhibitors or potassium-sparing diuretics, even dietary potassium intakes below the AI can cause hyperkalemia. Hyperkalemia can also occur in people with type 1 diabetes, congestive heart failure, adrenal insufficiency, or liver disease.
Hypertension medications that increase the risk of hyperkalemia include those that block the actions of the renin-angiotensin-aldosterone system (RAAS), including ACE inhibitors, ARBs, and aldosterone antagonists. These classes of medications act in part to decrease potassium excretion.
However, one controlled clinical trial found that an increase in dietary potassium over a 4-week period was safe in hypertensive subjects who had normal renal function and were receiving ACE inhibitor and/or ARB therapy. This finding suggests that individuals with preserved renal function may be able to increase dietary potassium even on RAAS-blocking medications, though individual monitoring is warranted.
Potential adverse indicators include gastrointestinal discomfort from certain forms of potassium supplements and arrhythmia from hyperkalemia. Although dietary potassium intake can be increased through behavioral change, there is a self-limiting aspect to such changes that makes toxic adverse effects from increases in dietary potassium intake unlikely.
In patients with non-dialysis dependent (NDD) chronic kidney disease stages 1–5, the National Kidney Foundation suggests an unrestricted potassium intake unless the serum potassium level is elevated. In hemodialysis patients, potassium intake should be up to 2.7–3.1 g/day; in peritoneal dialysis patients, close to 3–4 g/day, with adjustments based on serum potassium levels crucial in both cases.
The applicability of potassium AIs for persons with type 2 diabetes is uncertain, and its application will likely need to be individualized in consultation with a health care provider, with consideration of kidney function, medication use, and serum potassium concentrations.
The large cluster-randomized SSaSS trial showed that potassium-enriched salt significantly reduced the rates of fatal and non-fatal strokes, major cardiovascular events, and death in older adults with a history of stroke. Remarkably, the benefits appeared to be gained without significantly elevating the risk of clinical hyperkalemia. However, it should be noted that serial monitoring of potassium levels was not performed in the SSaSS trial, which limits conclusions about hyperkalemia risk in vulnerable subgroups.
Condiciones de salud que potasio puede ayudar a apoyar.
Higher potassium intake is associated with reduced arterial stiffness and lower blood pressure, key determinants of arterial health. Clinical data from the Jackson Heart Study and multiple RCTs support potassium's role in reducing pulse wave velocity and endothelial dysfunction. The FDA recognizes a qualified health claim linking potassium-rich diets to reduced risk of high blood pressure.
Potassium intake is inversely associated with blood pressure in numerous large clinical trials and meta-analyses. Increasing potassium reduces sodium retention, promotes vasodilation, and suppresses the renin-angiotensin system. The NIH ODS and WHO formally acknowledge its blood pressure-lowering effects.
Potassium plays a mechanistic role in insulin secretion and glucose uptake, with low serum potassium linked to impaired glucose tolerance. Observational and experimental studies show that potassium deficiency reduces pancreatic beta-cell insulin release, and low potassium is associated with higher 2-hour post-load glucose levels. Evidence is primarily mechanistic and observational rather than from large interventional trials.
Higher dietary potassium intake is associated with greater bone mineral density (BMD) in observational studies, particularly in postmenopausal women. The proposed mechanism involves potassium's alkalinizing salts neutralizing diet-induced acid load, thereby reducing calcium mobilization from bone. RCT evidence with potassium citrate shows reduced bone resorption markers.
Potassium is an essential mineral for nerve impulse transmission, muscle contraction, fluid balance, and blood pressure regulation. IOM-established AIs for children are 2,000–2,300 mg/day. It is present in children's MVMs such as ChildLife (potassium citrate), though typically at low doses relative to dietary requirements.
Potassium deficiency (hypokalemia) is a recognized complication of Crohn's disease caused by chronic diarrhea, vomiting, and intestinal fluid losses. WebMD and gastroenterology sources list potassium among the minerals commonly requiring supplementation in CD. It is essential for healthy muscle, cardiac, and cellular function.
Potassium is the principal intracellular cation and is essential for electrolyte balance, heart and muscle function, and nerve signaling. NIH/StatPearls and MedlinePlus classify it as one of the seven major electrolytes. Hypokalemia and hyperkalemia are clinically recognized electrolyte disorders with serious cardiovascular consequences. Potassium works with sodium to maintain the electrochemical gradients critical for all excitable tissues.
Potassium has robust clinical and epidemiological evidence supporting its role in cardiovascular health, primarily through blood pressure regulation and cardiac electrophysiological stability. Increased potassium intake significantly lowers blood pressure in hypertensive individuals and is associated with reduced stroke risk. Dyskalemia — both low and high potassium — is linked to cardiac arrhythmias and elevated cardiovascular mortality. The WHO formally recommends increased dietary potassium intake to reduce cardiovascular disease and stroke risk.
Potassium is critical for cardiac electrical conduction; hypokalemia increases risk of ventricular and supraventricular arrhythmias. The randomized POTCAST trial (n=1,200 ICD patients) demonstrated that targeting high-normal plasma potassium reduced unplanned hospitalizations for cardiac arrhythmias (6.7% vs 10.7%, HR 0.63) and appropriate ICD therapy. Potassium supplementation is a standard clinical approach to arrhythmia prevention.
Low dietary potassium intake is increasingly recognized as a risk factor for kidney injury and accelerated chronic kidney disease (CKD) progression. The kidney is the primary organ regulating potassium homeostasis, but potassium also reciprocally affects renal function. Higher potassium intake is associated with lower albuminuria and slower eGFR decline in population studies.
Potassium, particularly as potassium citrate, is a cornerstone pharmacological and dietary intervention for kidney stone prevention. It alkalinizes urine, raises urinary citrate, and reduces risk of recurrent calcium oxalate and uric acid stones. Potassium-magnesium citrate in a double-blind RCT reduced new stone formation by approximately 80% vs. placebo. Dietary potassium from fruits and vegetables is also inversely associated with stone risk in prospective cohort data.
Potassium deficiency (hypokalemia) is a well-established medical cause of muscle cramps and spasms, documented in NIH/StatPearls and standard medical references. Hypokalemia disrupts neuromuscular transmission and impairs muscle contraction, with symptoms including muscle weakness, cramps, and spasms. Correction of hypokalemia relieves cramp symptoms.
Potassium is essential for muscle cell function during and after exercise, with contraction causing efflux of K+ from skeletal muscle that is reversed during recovery. Interstitial accumulation of K+ during sustained exercise contributes to fatigue, and re-uptake is integral to post-exercise recovery. This is well-established mechanistically with supporting exercise physiology studies.
Potassium is fundamental to nerve cell membrane potential and action potential propagation. K+ channels control repolarization in neurons, and dyskalemias produce clinically documented neuromuscular dysfunction including weakness, paresthesia, and in severe cases paralysis. This relationship is mechanistically established and clinically validated.
Multiple observational studies and RCT evidence link higher potassium intake—particularly from alkaline-forming salts such as potassium citrate and bicarbonate—to reduced bone resorption markers and greater BMD, supporting a role in osteoporosis prevention. The mechanism centers on neutralizing diet-derived acid loads that would otherwise mobilize calcium from bone.
Potassium homeostasis is tightly coupled to exercise capacity, with interstitial K+ accumulation in working muscle a primary contributor to peripheral fatigue during sustained exercise. Adequate potassium status is necessary to maintain membrane excitability and delay fatigue onset. Exercise physiology research has established these dynamics in human subjects.
Potassium is a critical electrolyte for cellular membrane potential, muscle function, and cardiac rhythm, frequently depleted during illness through vomiting, diarrhea, and fever. Restoration of potassium balance is a fundamental component of post-illness recovery, particularly after gastrointestinal and febrile illnesses.
Potassium is the primary intracellular cation and its balance with sodium directly governs fluid distribution between body compartments. Higher potassium intake promotes renal sodium excretion (natriuresis) and reduces extracellular fluid retention. This mechanism is well-established in NIH/NCBI physiology literature and StatPearls, and potassium is a recognized clinical intervention for sodium-related fluid retention.
Sistemas corporales que potasio puede ayudar a apoyar.
Volver